IP Counsels Committee Conference

November 13-15, 2017 | Annapolis, MD

Schedule as of October 11, 2017

Sessions will be updated as they are finalized – Please check back

Monday, November 13, 2017

Registration Open
11:30 am - 4:30 pm

IPCC Business Meeting & Working Luncheon
12:00 pm – 3:15 pm
**Open to IP Counsels Committee company members only*

Refreshment Break
3:15 pm – 3:30 pm
Sponsored by: Marshall, Gerstein & Borun LLP

Opening Session: Avoiding the Ethical Minefield of Biopharmaceutical Patent Litigation and Prosecution
3:30 pm – 4:30 pm
Sponsored by: O'Melveny & Meyers LLP

This panel will offer an in-depth survey of the awarding of attorney's fees in biopharmaceutical patent litigation cases over the past two years. The panel's discussion will also specifically examine potential adverse evidentiary inferences flowing from litigation misconduct, as well as discuss common ethical violations observed by the USPTO.

Moderator: Filko Prugo, Registered Patent Attorney, O'Melveny & Meyers LLP
Speakers:

- Will Covey, Deputy General Counsel and Director for the Office of Enrollment and Discipline (OED), USPTO
- Lisa Pensabene, Head, Life Science Litigation, O'Melveny & Meyers LLP
- TBD

Welcome Remarks by Scott Kieff, former Commisioner, United States International Trade Commission
4:45 pm – 5:15 pm
Sponsored by: European Patent Office
Introductory Remarks by: Klaus-Peter Döpfer, PhD, Director, European Patent Office

Welcome Reception
5:30 pm – 7:30 pm
Sponosored by: Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

IP Counsels Committee Conference

November 13-15, 2017 | Annapolis, MD

Tuesday, November 14, 2017

Breakfast & Fireside Chat featuring Kevin Outterson, Professor of Law, Boston University

8:00 am – 9:15 am
Sponsored by Brinks Gilson & Lione
Moderator: Jennifer Fox, Shareholder, Brinks Gilson & Lione

Session 1: In the Hot Seat: Upcoming Cases in the Supreme Court and Federal Circuit

9:30 am – 10:45 am
Sponsored by: Choate Hall & Stewart LLP

This panel will tackle a number of issues from the Supreme Court including expected fallout from patent venue decision TC Heartland v. Kraft, IPR constitutionality, sovereign immunity in IPR's, among others presently under review.

Moderator: Eric Marandett, Co-chair, Intellectual Property Litigation Practice Group, Choate Hall & Stewart LLP

Speakers:

- Nathan Edwards, Director, Intellectual Property, Vertex Pharmaceuticals
- James Harrington, Senior Vice President, Chief Intellectual Property Counsel, Shire Pharmaceuticals
- Charlene Stern, Vice President, Legal, Editas Medicine
- Sophie Wang, Attorney, Choate Hall & Stewart LLP

Refreshment Break

10:45 am – 11:00 am
Sponsored by: Marshall, Gerstein & Borun LLP

Session 2: Double Patenting and Divisional Practice: How Do Worldwide Policies Impact LifeCycle Management Strategies?

11:00 am – 12:15 pm
Sponsored by: Choate Hall & Stewart LLP

This panel will review key decisions on double patenting and divisional practice, and furthermore will discuss current US PTO practices, will compare and contrast them with divisional practice in other jurisdictions, and will provide practical recommendations for lifecycle management that can avoid double patenting pitfall risks.

Moderator: Brenda H Jarrell, Co-chair, Life Sciences Group and the Intellectual Property Group, Choate Hall & Stewart LLP
Speakers:

- Andy Bentham, Partner, Patent Attorney, J A Kemp
- MJ Edwards, Intellectual Property Attorney, Gilead Sciences
- Jesse Fecker, Senior Director, Chief US Patent Counsel at Ferring Pharmaceuticals
- Kathleen Fonda, Senior Legal Advisor,Office of Patent Legal Administration, United States Patent and Trademark Office

Keynote Lunch featuring Judge Kathleen O'Malley, United States Court of Appeals, Federal Circuit

12:30 pm – 1:45 pm
Sponsored by: McNeill Baur PLLC
Introductory Remarks by: Ameila Feulner Baur, PhD, Founder and Managing Partner, McNeill Baur, PLLC

Session 3: Inherent Obviousness: How it is Being Applied and What it Means for your Cases

2:00 pm – 3:15 pm
Sponsored by: Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

What is inherent obviousness, where did it come from, and how is it being applied? What types of claims may be more susceptible to inherent obviousness challenges? What limits has the Federal Circuit placed on the doctrine? This panel will consider these factors and the implications on cases moving forward.

Moderator: Howard W. Levine, Partner, Finnegan, Henderson, Farabow Garrett & Dunner, LLP

Speakers:

- Kirsten Braun, PhD, Counsel, IP Litigation, AstraZeneca
- William B. Raich, PhD, Partner, Finnegan, Henderson, Farabow Garrett & Dunner, LLP
- Christopher Verni, Vice President, Chief IP Counsel, Sarepta Therapeutics

Refreshment Break

3:15 pm – 3:30 pm
Sponsored by: Marshall, Gerstein & Borun LLP

Session 4: Recent Trends in Post-Grant Proceedings and their Impact on Life Science Patents

3:30 pm – 4:45 pm
Sponsored by: Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

This panel will address the impact post-grant proceedings have had on life science patents, including recent cases and statistics on institution rates, final written decisions, and types of challenged claims. The panel will also provide perspectives on Oil States, sovereign immunity and IPR proceedings, and in-house counsel's views of the benefits and detriments of post-grant proceedings.

Moderator: Linda A. Wadler, Partner, Finnegan, Henderson, Farabow Garrett & Dunner, LLP

Speakers:

- Sanya Sukduang, Partner, Finnegan, Henderson, Farabow Garrett & Dunner, LLP
- Chuck Cappellari, Associate VP, Chief IP Counsel, Diagnostics, Hologic

Activity and Dinner Reception

5:30 pm – 8:30 pm
Sponsored by: McDonnell Boehnen Hulbert & Berghoff LLP

IP Counsels Committee Conference

November 13-15, 2017 | Annapolis, MD

Wednesday, November 15, 2017

Breakfast
8:00 am – 9:15 am

Session 5
9:30 am – 10:45 am
Sponsored by: Fitzpatrick

Refreshment Break
10:45 am – 11:00 am
Sponsored by: Marshall, Gerstein & Borun LLP

Session 6
11:00 am – 12:15 pm
Sponsored by: Fitzpatrick

Adjournment